Guideline Recommendations for First‑Line Antiretroviral Therapy in Treatment‑Naive Adults

First‑Line Integrase Inhibitor–Based Regimens

• Bictegravir + tenofovir alafenamide + emtricitabine as a single‑tablet regimen is recommended for most newly diagnosed adults because it provides the highest efficacy, best tolerability, and the strongest barrier to resistance among first‑line options. 1, 2
• Dolutegravir + tenofovir alafenamide + emtricitabine is equally effective, supported by extensive long‑term safety data, and is available as either a single tablet or separate pills. 1, 2
• Dolutegravir + abacavir + lamivudine (single tablet) may be used only after mandatory HLA‑B*5701 testing to avoid potentially life‑threatening hypersensitivity reactions. 1, 2, 3

Alternative Regimens When Integrase Inhibitors Cannot Be Used (AIa Evidence)

• Darunavir + cobicistat + tenofovir alafenamide + emtricitabine is the preferred protease‑inhibitor option, offering a high resistance barrier and usefulness when integrase‑inhibitor resistance is suspected. 1
• Darunavir + ritonavir + tenofovir alafenamide + emtricitabine provides an alternative boosting strategy to cobicistat. 1, 3
• Elvitegravir + cobicistat + tenofovir alafenamide + emtricitabine is another integrase‑inhibitor regimen but has a higher potential for drug‑drug interactions due to cobicistat. 1
• Raltegravir + tenofovir alafenamide + emtricitabine, a first‑generation integrase inhibitor, requires twice‑daily dosing. 1, 3

Regimens to Avoid or Use With Caution

• Rilpivirine‑based regimens are contraindicated when baseline HIV‑1 RNA > 100 000 copies/mL or CD4 < 200 cells/µL because of a markedly increased risk of virologic failure. 4, 1
• Efavirenz + tenofovir disoproxil fumarate + emtricitabine should be reserved for patients with active tuberculosis co‑infection; it is associated with neuropsychiatric adverse effects and an elevated risk of suicidality. 4, 1
• NNRTI‑containing regimens and abacavir should not be used for rapid ART initiation because baseline resistance testing and HLA‑B*5701 results are required first. 1, 2, 3

Critical Pre‑Treatment Testing (Do Not Delay ART Initiation)

• Initiate antiretroviral therapy immediately at diagnosis; obtain baseline labs but do not wait for results before starting treatment. 1, 3
• Required baseline assessments include:

Special Population Considerations

Renal Impairment or Osteoporosis

• Tenofovir disoproxil fumarate should be avoided; tenofovir alafenamide is preferred because of superior renal and bone safety profiles. 1, 2

Pregnancy

• Dolutegravir + tenofovir alafenamide + emtricitabine is the preferred regimen during pregnancy; bictegravir + tenofovir alafenamide + emtricitabine is an acceptable alternative. 1, 2

Advanced Immunosuppression (CD4 ≤ 35 cells/µL)

• The same preferred integrase‑inhibitor regimens (bictegravir‑ or dolutegravir‑based) are recommended; rilpivirine must be avoided. Initiate Pneumocystis pneumonia prophylaxis when CD4 < 200 cells/µL. 1, 3

High Baseline Viral Load (>100 000 copies/mL)

• Use preferred integrase‑inhibitor regimens and avoid rilpivirine entirely because high viral load predicts treatment failure. 4, 1

Tuberculosis Co‑Infection

• Efavirenz + tenofovir disoproxil fumarate + emtricitabine is recommended due to extensive experience with concurrent rifampin therapy. 4, 1

Monitoring After Treatment Initiation

Viral Load Monitoring

• Obtain HIV‑1 RNA at 4–6 weeks after ART start to assess initial response.
• Continue testing every 4–6 weeks until the viral load is < 50 copies/mL (target by 24 weeks).
• Once suppressed, monitor every 3 months during the first year, then every 6 months after 1–2 years of sustained suppression. 1

CD4 Monitoring

• Measure CD4 count every 3–6 months during the first year.
• After the first year, test every 6 months until the CD4 rises above 250 cells/µL for at least one year; thereafter, CD4 monitoring may be discontinued if viral suppression is maintained. 1

Common Pitfalls to Avoid

• Failing to perform HLA‑B*5701 testing before prescribing abacavir can lead to fatal hypersensitivity reactions. 1, 2, 3
• Delaying ART initiation while awaiting laboratory results reduces the benefits of early treatment; start ART promptly unless the patient is not ready to commit. 1, 3
• Using rilpivirine in patients with high viral load or low CD4 counts results in markedly higher virologic failure rates. 4, 1
• Prescribing tenofovir disoproxil fumarate to patients with renal disease or osteoporosis should be avoided; switch to tenofovir alafenamide. 1, 2

Initial Regimens for HIV Treatment

First-Line Regimens

• The American College of Cardiology is not applicable here, however, the recommended initial regimens for HIV treatment are integrase strand transfer inhibitor (InSTI)-based combinations, with bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) being the preferred first-line regimen for most patients due to its high efficacy, favorable side effect profile, and high barrier to resistance 6, 7
• Dolutegravir plus tenofovir alafenamide/emtricitabine (DTG + TAF/FTC) is a highly effective combination with a strong resistance profile 6, 7
• Dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) is an effective regimen but requires HLA-B*5701 testing before use to prevent hypersensitivity reactions 6, 8

Alternative Regimens

• Dolutegravir/lamivudine (DTG/3TC) is a two-drug regimen recommended only if HIV RNA level is <500,000 copies/mL, no lamivudine resistance, and no HBV co-infection 7, 9
• Darunavir (boosted with ritonavir or cobicistat) plus TAF/FTC is recommended when InSTI resistance is suspected, particularly after exposure to long-acting cabotegravir as PrEP 7, 10

Key Considerations for Regimen Selection

• For patients with renal impairment, the guideline recommends avoiding TDF-containing regimens 10
• For patients with osteoporosis, the guideline prefers TAF over TDF 10
• For patients with hepatitis B co-infection, the guideline recommends using regimens containing TAF or TDF plus FTC or 3TC (avoid DTG/3TC) 6, 7
• For pregnant patients, DTG plus TAF/FTC is the recommended regimen; BIC/TAF/FTC is an alternative 7

Drug-Specific Considerations

• HLA-B*5701 testing is mandatory before using abacavir to prevent potentially life-threatening hypersensitivity reactions 6, 8
• Cobicistat-boosted regimens (EVG/c, DRV/c) have more interactions 6
• Rifampin cannot be used with many regimens including BIC/TAF/FTC, DTG/3TC, EVG/COBI, and rilpivirine 7

Efficacy and Safety Data

• DTG/3TC demonstrated non-inferiority to 3-drug regimens but should only be used in specific patient populations 7
• TAF has fewer renal and bone toxicities compared to TDF, especially when used with pharmacological boosters 6

Common Pitfalls to Avoid

• Not testing for HLA-B*5701 before prescribing abacavir-containing regimens, which can lead to potentially life-threatening hypersensitivity reactions 6, 8
• Starting DTG/3TC without confirming HIV RNA level, resistance status, and HBV status 7
• Overlooking drug interactions, particularly with cobicistat-boosted regimens or in patients taking rifampin 6, 7
• Delaying ART initiation, which can lead to poorer outcomes; treatment should be started as soon as possible after diagnosis 6, 9

Monitoring After Initiation

• Measure viral load 4-6 weeks after starting ART to assess initial response 9
• Once viral suppression is achieved, monitor every 3 months until suppression is maintained for at least 1 year 9
• After 1 year of viral suppression, monitoring can be reduced to every 6 months 9
• Regularly assess for drug-specific toxicities and adherence 6